Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Cell Sheet-Based Gene Therapy Market Value Growth And Long-Term Outlook
The cell sheet-based gene therapy market has witnessed rapid growth in recent years. It is anticipated to expand from $0.68 billion in 2025 to $0.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.4%. This historical market expansion can be ascribed to several factors, including increasing advancements in tissue engineering research, the early adoption of regenerative medicine techniques, the growth in cell-based therapeutic studies, improvements in gene delivery technologies, and the expansion of translational research initiatives.
The cell sheet-based gene therapy market size is projected for significant expansion over the upcoming years, with an anticipated growth to $1.34 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 14.6%. This expected growth is driven by factors such as a heightened demand for localized regenerative treatments, an increase in clinical trials involving gene-modified cell therapies, broader applications in oncology and cardiology, increased investments in advanced tissue engineering, and a stronger emphasis on precision regenerative medicine. Key trends during this period include the development of multilayered and co-culture cell sheet technologies, a greater focus on localized gene expression therapies, the expanding integration of regenerative medicine approaches, a wider adoption of stem-cell derived cell sheets, and an improved emphasis on tissue integration and longevity.
Get A Free Sample Report With In-Depth Market Insights:
Cell Sheet-Based Gene Therapy Market Demand Drivers: What’s Powering Industry Growth?
The increasing occurrence of chronic and degenerative illnesses is anticipated to fuel expansion within the cell sheet-based gene therapy market. These conditions are defined as persistent health issues, such as cardiovascular disorders, neurodegenerative diseases, diabetes, and genetic disorders, which cause progressive damage to tissues and organs and necessitate ongoing therapeutic management. The growing number of elderly individuals and extended life expectancies in both advanced and emerging economies are contributing to the increased incidence of these diseases. Cell sheet-based gene therapy facilitates regenerative treatments for chronic and degenerative diseases by providing localized tissue repair and continuous gene delivery through layered living cell constructs, thereby enhancing tissue integration and achieving superior long-term therapeutic results. For example, in April 2025, the International Diabetes Federation (IDF), a non-profit organization based in Belgium, reported that 589 million individuals globally had diabetes in 2024, with this number expected to climb to 853 million by 2050. Consequently, the escalating prevalence of chronic and degenerative diseases is propelling the growth of the cell sheet-based gene therapy market.
Cell Sheet-Based Gene Therapy Market Segmentation: How Does The Market Break Down By Category?
The cell sheet-based gene therapy market covered in this report is segmented –
1) By Cell-Sheet Type: Monolayer Cell-Sheet Type; Co-Culture Cell-Sheet Type; Multilayered Cell-Sheet Type; Other Cell-Sheet Types
2) By Technology Type: Cell Sheet-Based Engineering Techniques; Gene Delivery Methods
3) By Source Type: Autologous; Allogenic; Stem-Cell Derived
4) By Application: Oncology; Ophthalmology; Genetic Disorders; Cardiology; Other Applications
5) By End-User: Hospitals And Clinics; Research And Academic Institutions; Biotech And Pharma Companies; Other End-Users
Subsegments:
1) By Monolayer Cell-Sheet Type: Cardiomyocyte Sheets; Epithelial Cell Sheets; Mesenchymal Stem Cell Sheets; Other Monolayer Cell Sheets
2) By Co-Culture Cell-Sheet Type: Fibroblast + Stem Cell Sheets; Endothelial + Smooth Muscle Cell Sheets; Other Co-Culture Combinations
3) By Multilayered Cell-Sheet Type: Triple-Layered Sheets; Double-Layered Sheets; Other Multilayered Configurations
4) By Other Cell-Sheet Types: Genetically Modified Cell Sheets; Hybrid Cell Sheets; Other Novel Or Experimental Sheets
Cell Sheet-Based Gene Therapy Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies within the cell sheet-based gene therapy market are concentrating on creating advanced solutions, particularly autologous gene-corrected cell sheet products. These products aim to improve regenerative medicine outcomes, enhance treatment accuracy, and achieve lasting tissue repair by integrating engineered cells with scaffold-free sheet constructs for precise gene delivery and wound healing. Autologous gene-corrected cell sheet products involve genetically modifying a patient’s own cells outside the body, growing them into sheet constructs that maintain cell-to-cell connections and extracellular matrix integrity, and then applying them directly to injured tissues to encourage functional integration and sustained therapeutic benefits. As an illustration, in April 2025, the US-based biopharmaceutical firm Abeona Therapeutics Inc. obtained approval from the US-based federal agency Food and Drug Administration (FDA) for zevaskyn (prademagene zamikeracel). This therapy is intended for the treatment of wounds in both adult and pediatric patients suffering from recessive dystrophic epidermolysis bullosa (RDEB). Zevaskyn works by delivering the functional COL7A1 gene through genetically corrected cell sheets, facilitating significant wound healing and pain reduction with a single application, and sustaining type VII collagen expression at wound sites, thereby representing a significant advancement in regenerative therapy and setting a precedent for future innovations in cell sheet-based gene therapy.
Cell Sheet-Based Gene Therapy Market Company Landscape And Competitive Strategy
Major companies operating in the cell sheet-based gene therapy market are Hitachi Ltd., Thermo Fisher Scientific, Fujifilm Cellular Dynamics Inc. (FCDI) (FUJIFILM Holdings Corporation), Lonza Group AG, teijin regenet co. ltd., Terumo Corporation, Nikon CeLL innovation Co. Ltd., Rohto Pharmaceutical Co. Ltd., BioBridge Global, AGC Biologics, Shibuya Corporation (Shibuya Kogyo Co. Ltd.), National Resilience Inc., Takara Bio Inc., Japan Tissue Engineering Co. Ltd. (J-TEC), Medipost Co. Ltd., Cell Therapies Pty Ltd, CellSeed Inc., SCTbio, Abeona Therapeutics Inc., Foundation ENEA Tech, Cyto-Facto Inc., ENCELL Co. Ltd.
View The Full Cell Sheet-Based Gene Therapy Market Report:
Cell Sheet-Based Gene Therapy Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the cell sheet based gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell sheet-based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
